A person holds an Ozempic injection pen near the abdomen.
Weight Loss

Ozempic Is Changing Snacks and You May Notice It Soon

I noticed it in the freezer aisle first. A frozen meal I sometimes grab on busy nights had a little badge on the front calling it GLP-1 friendly, and I stood there longer than I’d like to admit, trying to work out what that meant.

Now the cracker brand I grew up with is launching a protein version. None of this is random.

Purchase data shows that households using drugs like Ozempic, Wegovy, and Zepbound buy noticeably fewer snacks, and food companies are adjusting. Some of what you’ll see on shelves this fall is a real change. Some of it is a new label on familiar food.

What GLP-1 Households Stopped Buying, According to Real Grocery Receipts

A grocery cart with bananas, strawberries, and packaged food in a supermarket aisle.
Savory snack purchases fell by about 10%, one of the sharpest shifts seen within six months of GLP-1 use

The strongest evidence comes from Cornell researchers who matched survey answers about GLP-1 use with purchase records from a Numerator panel of about 150,000 U.S. households.

Their study in the Journal of Marketing Research, published December 18, 2025, compared households that started a GLP-1 with similar households that did not.

Spending category Change within six months of starting
Total groceries Down 5.3% on average
Groceries, higher-income households Down more than 8%
Savory snacks Down about 10%
Fast food and coffee shops Down about 8%
Yogurt, fresh fruit, nutrition bars, meat snacks Small increases

These are receipts rather than food diaries, so I take them seriously. They still show what a household bought, not what one person ate. Sweets, baked goods, and cookies fell by similar amounts.

Roughly a third of users stopped the medication during the study, and their spending moved back toward pre-drug levels, with slightly more candy and chocolate in the cart than before.

Snack Companies Are Shrinking Packs, Adding Protein and Relabeling Meals

Cheerios Protein cereal boxes sit beside a Full O’ Good slogan on a yellow backdrop.
Conagra’s GLP-1 badge shows how fast brands now adapt labels even when the recipe stays the same

I went through the company announcements expecting a few press releases and found a pattern instead. In February, Reuters reported that nearly three dozen companies outside health care had brought up GLP-1 drugs or weight loss on earnings calls in early 2026, up from 14 a year earlier.

These companies clearly aren’t treating it as a fad anymore. Their moves fall into four groups:

  • Shrinking the snack. PepsiCo and Coca-Cola are pushing smaller packs and shorter ingredient lists this year, which reads to me like planning for people who eat less.
  • Adding protein. General Mills launched a higher-protein Cheerios in December 2024, and Pepperidge Farm is bringing Goldfish with 6 grams of protein per serving to Walmart in October.
  • Relabeling. Conagra’s December 2024 press release announced a GLP-1 friendly badge for 26 Healthy Choice frozen meals, with the recipes unchanged. This is the group I’d watch most carefully.
  • Leaving the snack aisle. PepsiCo is moving into fresh foods like guacamole and gazpacho.

How Many People Are Actually Taking These Drugs

After reading the Cornell numbers, my first question was how many people we’re actually talking about. More than I guessed.

In a KFF poll taken in late October and early November 2025, about one in eight adults said they were currently taking a GLP-1 for weight loss, diabetes or another condition. The names confused me too.

Ozempic is approved for type 2 diabetes, and Wegovy is the same drug, semaglutide, approved for weight management. Most of us just say “Ozempic” for all of them. My guess is the number keeps climbing, since the FDA approved the first GLP-1 pill for weight management in December 2025.

Did you know?

Gallup, which asks only about weight-loss use, found an even steeper climb. In its survey of 5,065 adults conducted May 28 to June 5, 2026, 11% said they currently take a GLP-1 for weight loss, up from 3% in 2024. Gallup revised those figures on September 8 after changing how it weights responses.

The Headline That Promised More Than the Study Found

A headline that made the rounds last year said scientists had found why Ozempic changes the kinds of food people eat. I’ll admit I clicked hoping for a tidy explanation.

The study behind it, published in Food Quality and Preference by University of Arkansas researchers, was an online survey of nearly 2,000 U.S. adults conducted in May 2024. People estimated their own daily calories on a scale and reported which foods they ate more or less of.

Current users reported eating less, and the authors estimated the drop at roughly 720 to 990 calories a day for people taking a GLP-1 for weight loss. Processed foods, soda, refined grains, and beef were the foods most often cut back.

What surprised me is that users still rated those foods as desirable. That’s useful. It isn’t an explanation of why, and self-reported calories are rough.

I had a similar reaction to a study of water between bites at lunch. People who drank more water with their meals also ate more food, but the researchers could not prove the water caused it. A pattern can be real without a clear explanation for it.

What a “GLP-1 Friendly” Badge Does and Doesn’t Tell You


This is the part that sent me back to the freezer case. Conagra says its badge flags meals that are high in protein, low in calories and a good source of fiber, and that the USDA reviewed the labels.

Those three phrases have real rules behind them. “GLP-1 friendly” is different. I couldn’t find any federal definition for it, which makes it closer to a helpful nudge than a standard.

Under federal labeling rules for most packaged foods, “high” or “excellent source” means one standard reference serving provides at least 20% of the Daily Value for that nutrient. “Good source” means 10% to 19%. Meal products and USDA-regulated foods have their own versions of these rules.

None of this means the meals are a bad pick. It means the badge is a summary written by the company. The Nutrition Facts panel is still where the grams live.

Big Forecasts Are Not the Same as Sales Numbers

You’ll see big dollar figures in coverage of this story, and they deserve a second look. They are estimates about the future, built on assumptions about how many people will take these drugs and for how long. Remember that Cornell found spending bounced back when people stopped.

Figure Source What kind of number it is
Savory snack spending down about 10% Cornell study Measured, GLP-1 households only
Up to $12 billion in lost snack sales EY-Parthenon, via Reuters Forecast for the next decade
$73 billion in brand value at risk Brand Finance, September 2026 Estimate for the 100 most valuable food brands worldwide

Brand Finance named Lay’s as the most exposed brand, with $6.8 billion of its value tied to vulnerable categories. That’s a valuation exercise, not a report that Lay’s sales fell by that amount.

The firm’s valuation director said the real risk is everyday purchases getting smaller or less frequent, rather than people giving up chips entirely.

GLP-1 Users Eat Less, So Protein and Nutrients Matter More

A bowl with grilled chicken, rice, sweet potato, avocado, beets, lentils, and tomatoes.
GLP-1 therapy can reduce lean mass as well as fat mass, so adequate protein and resistance exercise deserve extra attention

When you’re eating much less, each snack matters more. Four medical and nutrition groups addressed this in a joint advisory published May 30, 2025, telling clinicians that people on these drugs need enough nutrients packed into much smaller amounts of food.

I also think it matters what happens beyond weight loss. In a controlled trial of keto, Mediterranean, and very-low-fat diets, all three groups lost about 10% of their body weight.

Liver fat fell much more on keto. The trial did not involve GLP-1 drugs, but it gave me another reason to pay attention to health markers beyond the scale.

Priorities they flagged include:

  • Enough protein, along with strength training, to help preserve muscle
  • Preventing vitamin and mineral shortfalls
  • Handling side effects such as nausea, which can shrink the list of foods that sound tolerable

There are hints the gap is real. A preliminary study of 387 adults recruited from Polish online support groups found fewer than 10% met recommended protein intake, based on two-day food diaries.

It’s a small, self-selected group, so I wouldn’t generalize. If this is you, your prescriber or a registered dietitian can help you set targets that fit.

The question of muscle loss also came up in a 12-week creatine trial. Participants who took creatine alongside a calorie-reduced diet and an exercise program gained lean tissue as their body fat fell. The trial did not test GLP-1 drugs, but it gave me another reason to pay attention to muscle as well as weight.

How I’m Going to Read Snack Labels This Fall

After all this reading, I didn’t come away with new food rules. I came away with a habit I already had, just sharper. The front of a package is where the marketing budget goes, so the back is where I’ll spend my extra few seconds. This is what I’m checking now:

  • The serving size first. The FDA’s guide to the Nutrition Facts label explains that every nutrient amount is based on the serving listed at the top, so I only compare bags on equal servings.
  • Protein in grams, not adjectives. Goldfish calls its new 6-gram crackers double the original, but reports disagree on the original’s number. I’ll check both bags myself.
  • The badge against the panel. A “GLP-1 friendly” label is the company’s summary. The panel is the evidence.
  • The unit price. Smaller packs can quietly cost more per ounce.

My Final Perspective

A GLP-1 injection pen sits on a table beside a medication bottle and needle cap.
For food brands, smaller appetites may make portion size just as important as protein, calories, and price

The protein Goldfish reach Walmart in October, and I’ve already made room on my counter. I’ll set a bag of each flavor next to the originals and compare calories and protein for the same 55-piece serving before deciding whether the upgrade matters to me.

The next badge I spot in the freezer case gets the same treatment. If you’re taking a GLP-1, bring your snack questions to your prescriber, who knows your dose and side effects.

And with about one in eight adults already on these drugs, someone at your table may be reading those labels with a very different appetite.

Frequently Asked Questions

Will “GLP-1 friendly” foods help me lose weight if I’m not on the drug?

Not in any special way. The badge highlights meals with more protein, fewer calories, and a source of fiber. Such foods can fit a calorie deficit even if you do not use medication.

The food does not copy the effect of a GLP-1 drug. Its value depends on how it fits into your daily diet and how well it controls hunger.

Are protein-boosted snacks healthier than regular versions?

Not automatically, and neither version is “bad.” Extra protein may help some people feel full for longer. Compare the full nutrition label for the same serving size, with attention to calories, sodium, fiber, and added sugar.

A few extra grams of protein in crackers make only a modest difference. If protein is your main goal, foods such as yogurt, eggs, or beans may provide much more.

Are compounded or online GLP-1 drugs the same as Ozempic or Wegovy?

No. The FDA says compounded GLP-1 drugs are not FDA-approved. The FDA does not review such products for safety, effectiveness, or quality before sale.

The agency has also received reports of dose errors and has issued warnings about fraudulent products and counterfeit Ozempic. The FDA recommends a prescription from a doctor and purchase through a state-licensed pharmacy.

Do GLP-1 drugs change how food tastes?

No firm answer exists yet. Some users report changes in taste or in how appealing certain foods seem. Researchers have proposed taste changes as one possible reason for lower food intake, but current evidence remains limited.

A University of California, Davis study on cravings and diet quality among GLP-1 users remains underway, with main results expected in 2027.

Erin Walker
Erin Walker
Erin Walker is the founder and writer behind Calorie Deficit. She writes about calorie deficits, everyday nutrition and smarter grocery choices, checking every article against reliable sources. She is not a physician or registered dietitian.
http://caloriedeficit.org